Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits.

Fiche publication


Date publication

janvier 2021

Journal

Atherosclerosis

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LAGROST Laurent, Pr MASSON David, Dr AIRES Virginie, Mme BATAILLE Amandine


Tous les auteurs :
Gautier T, Deckert V, Aires V, Le Guern N, Proukhnitzky L, Patoli D, Lemaire S, Maquart G, Bataille A, Xolin M, Magnani C, Masson D, Harscoët E, Da Silva B, Houdebine LM, Jolivet G, Lagrost L

Résumé

Apolipoprotein (apo) C1 is a 6.6 kDa protein associated with HDL and VLDL. ApoC1 alters triglyceride clearance, and it also favors cholesterol accumulation in HDL, especially by inhibiting CETP in human plasma. Apart from studies in mice, which lack CETP, the impact of apoC1 on atherosclerosis in animal models expressing CETP, like in humans, is not known. This study aimed at determining the net effect of human apoC1 on atherosclerosis in rabbits, a species with naturally high CETP activity but with endogenous apoC1 without CETP inhibitory potential.

Mots clés

Apolipoprotein C1, Atherosclerosis, CETP, HDL, Rabbit, Transgenic

Référence

Atherosclerosis. 2021 Jan 12;320:10-18